Cordlife GroupCLIFF 33 Shareholder Yield % is 1.43% as of Mar. 2026, which is 56% below its 10-year median of 3.28. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Cordlife Group ranks better than 62.38% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Cordlife Group's Shareholder Yield % was 1.43%.
Cordlife Group (OTCPK:CLIFF) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Cordlife Group Shareholder Yield % Related Terms
Cordlife Group Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: Shareholder Yield % Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Shareholder Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Cordlife Group (CLIFF) has a Shareholder Yield % of 1.43% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cordlife Group and its competitors. This is 56% below median its historical median of 3.28. According to the industry distribution chart, Cordlife Group ranks #76 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 37.6%.
Is Cordlife Group's Shareholder Yield % too high?
Cordlife Group's current Shareholder Yield % of 1.43% is 56% below median its 10-year median of 3.28. Based on the distribution chart, Cordlife Group ranks #76 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Shareholder Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #76 out of 202 companies for Shareholder Yield %. This puts Cordlife Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Diagnostics & Research company?
A good Shareholder Yield % depends on the Medical Diagnostics & Research industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cordlife Group and its competitors. Cordlife Group's current Shareholder Yield % is 1.43%, which is 56% below median its own 10-year median of 3.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $0.15 — trading 24.8% below its estimated fair value. The current Shareholder Yield % is 1.43%, which is 56% below median its 10-year median of 3.28. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Shareholder Yield % is 1.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 24.8% below its estimated GF Value™ of $0.20.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
Shareholder Yield %: 1.43% (56% below median its 10-year median of 3.28)
GF Value™: $0.20 vs. price of $0.15 (24.8% below fair value)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
